These findings lead us to suggest that early intervention to antagonise the effects of E2 or reduce serum E2 levels would be effective for the prevention of breast cancer in BRCA1 or BRCA2 mutation carriers. This evidence concerns the gene BRCA2 and breast carcinoma.